{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:25:39Z","timestamp":1777875939555,"version":"3.51.4"},"reference-count":50,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Thyroid\u00ae"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Evidence is needed on the risks and benefits of combination therapy with levothyroxine (LT4)+liothyronine (LT3) for the treatment of hypothyroidism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective and Methods:<\/jats:title>\n                    <jats:p>We performed a randomized, double-blind placebo-controlled study to assess the effects of LT4+LT3 therapy versus LT4+placebo in a homogeneous group of athyreotic patients, without cardiovascular risk factors during long-term replacement monotherapy with LT4. The primary objective of the study was to assess the effects of combination LT4+LT3 therapy on heart rate, cardiac rhythm, and sensitive cardiovascular parameters of cardiac morphology and function by means of electrocardiography and Doppler echocardiography. The secondary objective of the study was to evaluate patient compliance, tolerability, and potential adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Thirty-eight patients with postsurgical hypothyroidism satisfying the inclusion criteria were selected from a group of 300 patients with low-risk thyroid cancer followed for a routine follow-up; they were randomized to receive LT4+LT3 or LT4+placebo. Twenty-four patients were evaluated after 1 year of treatment. All clinical and laboratory parameters were compared with the results obtained from 50 healthy euthyroid volunteers without comorbidities, matched for gender, age, physical activity, and lifestyle. Participants and clinicians remained blinded to the treatment allocation. After 1 year of combination therapy, a significant improvement in the diastolic function, evidenced by a significant reduction in the E\/e\u2032 ratio (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.046) and its positive trend over time, was observed in the LT4+LT3 group versus the LT4+placebo group. In addition, the univariate analyses showed a significant relationship between free triiodothyronine (fT3) levels (in pg\/mL) with \u0394 of variation of the E\/e\u2032 ratio in the LT4+LT3 group (standardized \u03b2 coefficient\u2009=\u20090.603 [confidence interval: 0.001\u20131.248],\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.050) after combination therapy. No adverse events including tachycardia, arrhythmias, atrial fibrillation, or other important events occurred between the first administration and the end of the study.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In this preliminary report, combination treatment with LT4+LT3 induced favorable changes in cardiovascular parameters of diastolic function without any adverse cardiovascular events. Trial Registration: EUDRACT number: 2017-001261-25.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/thy.2023.0135","type":"journal-article","created":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T13:17:39Z","timestamp":1695129459000},"page":"1402-1413","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":15,"title":["Preliminary Results of a Double-Blind Randomized Controlled Trial Evaluating the Cardiometabolic Effects of Levothyroxine and Liothyronine Compared to Levothyroxine with Placebo in Athyreotic Low-Risk Thyroid Cancer Patients"],"prefix":"10.1177","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8360-4464","authenticated-orcid":false,"given":"Bernadette","family":"Biondi","sequence":"first","affiliation":[{"name":"Division of Internal Medicine and Cardiovascular Endocrinology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Pucci","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine and Cardiovascular Endocrinology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilda","family":"Pontieri","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine and Cardiovascular Endocrinology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Formisano","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Esposito","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine and Cardiovascular Endocrinology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,12,7]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2014.0028"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1210\/er.2013-1083"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2021"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2018.18"},{"key":"e_1_3_6_6_2","unstructured":"The IQVIA Institute. Medicine Use and Spending in the U.S. A Review of 2018 and Outlook to 2023. Institute Report May 09 2019. Available from: https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports\/medicine-use-and-spending-in-the-us-a-review-of-2018-and-outlook-to-2023 [Last accessed: January 2023]."},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.299.7.769"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1301"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-2587"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2008.03267"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-4092"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-2660"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.7326\/M15-1799"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI77588"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-3399"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0720"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2021.0270"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1159\/000339444"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-016-0511-z"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad224"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1988.00380020131018"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2009.0311"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2015.0020"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jex244"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jev014"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jev076"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjhyper.2004.08.032"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2016.01.011"},{"key":"e_1_3_6_29_2","unstructured":"SmPC of Liotir\u00ae (liothyronine sodium) revised by AIFA on May 15 2015."},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00168"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.02.045"},{"key":"e_1_3_6_32_2","unstructured":"Biondi B. Chapter 96: Endocrine Disorders and Cardiovascular Disease. In: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine Eleventh Edition. (Libby P Bonow RO Mann DL et al. eds.) Elsevier: Philadelphia USA; 2021; pp. 1791\u20131815."},{"key":"e_1_3_6_33_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1329"},{"key":"e_1_3_6_34_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01361"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-02302"},{"key":"e_1_3_6_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2018.10.008"},{"key":"e_1_3_6_37_2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac635"},{"key":"e_1_3_6_38_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2022.0209"},{"key":"e_1_3_6_39_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.84.6.5733"},{"key":"e_1_3_6_40_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.3.7291"},{"key":"e_1_3_6_41_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.9052"},{"key":"e_1_3_6_42_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2017.0517"},{"key":"e_1_3_6_43_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022552"},{"key":"e_1_3_6_44_2","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jes216"},{"key":"e_1_3_6_45_2","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jes216"},{"key":"e_1_3_6_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2004.12.017"},{"key":"e_1_3_6_47_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.4.5728.145"},{"key":"e_1_3_6_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2004.02050"},{"key":"e_1_3_6_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13052"},{"key":"e_1_3_6_50_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0388"},{"key":"e_1_3_6_51_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2021.0634"}],"container-title":["Thyroid\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/thy.2023.0135","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/thy.2023.0135","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/thy.2023.0135","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:10:39Z","timestamp":1777587039000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/thy.2023.0135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":50,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1089\/thy.2023.0135"],"URL":"https:\/\/doi.org\/10.1089\/thy.2023.0135","relation":{},"ISSN":["1050-7256","1557-9077"],"issn-type":[{"value":"1050-7256","type":"print"},{"value":"1557-9077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12]]}}}